Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 765

2.

Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system.

Yoshimura I, Ikegami S, Suzuki S, Tadakuma T, Hayakawa M.

J Urol. 2002 Dec;168(6):2659-64.

PMID:
12442005
3.

Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors.

Wu L, Matherly J, Smallwood A, Adams JY, Billick E, Belldegrun A, Carey M.

Gene Ther. 2001 Sep;8(18):1416-26.

4.

Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.

Spitzweg C, Zhang S, Bergert ER, Castro MR, McIver B, Heufelder AE, Tindall DJ, Young CY, Morris JC.

Cancer Res. 1999 May 1;59(9):2136-41.

5.

Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer.

O'Keefe DS, Uchida A, Bacich DJ, Watt FB, Martorana A, Molloy PL, Heston WD.

Prostate. 2000 Oct 1;45(2):149-57.

PMID:
11027414
7.

Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines.

Lee SE, Jin RJ, Lee SG, Yoon SJ, Park MS, Heo DS, Choi H.

Anticancer Res. 2000 Jan-Feb;20(1A):417-22.

PMID:
10769689
8.

Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer.

Li X, Zhang YP, Kim HS, Bae KH, Stantz KM, Lee SJ, Jung C, Jiménez JA, Gardner TA, Jeng MH, Kao C.

Cancer Res. 2005 Mar 1;65(5):1941-51.

9.

Expression of Drosophila Ca2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival.

Zhang L, Brereton HM, Hahn M, Froscio M, Tilley WD, Brown MP, Barritt GJ.

Cancer Gene Ther. 2003 Aug;10(8):611-25.

PMID:
12872143
10.

Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen.

Pang S, Dannull J, Kaboo R, Xie Y, Tso CL, Michel K, deKernion JB, Belldegrun AS.

Cancer Res. 1997 Feb 1;57(3):495-9.

12.

Prostate-specific targeting using PSA promoter-based lentiviral vectors.

Yu D, Chen D, Chiu C, Razmazma B, Chow YH, Pang S.

Cancer Gene Ther. 2001 Sep;8(9):628-35.

13.

Use of the PSA enhancer core element to modulate the expression of prostate- and non-prostate-specific basal promoters in a lentiviral vector context.

Chapel-Fernandes S, Jordier F, Lauro F, Maitland N, Chiaroni J, de Micco P, Mannoni P, Bagnis C.

Cancer Gene Ther. 2006 Oct;13(10):919-29. Epub 2006 Jun 2.

PMID:
16741521
15.

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.

Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT.

Prostate. 2003 Mar 1;54(4):249-57.

PMID:
12539223
16.

Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.

Gotoh A, Ko SC, Shirakawa T, Cheon J, Kao C, Miyamoto T, Gardner TA, Ho LJ, Cleutjens CB, Trapman J, Graham FL, Chung LW.

J Urol. 1998 Jul;160(1):220-9.

PMID:
9628654
18.

Human prostate cancer progression models and therapeutic intervention.

Chung LW, Kao C, Sikes RA, Zhau HE.

Hinyokika Kiyo. 1997 Nov;43(11):815-20. Review.

19.
20.

Recombinant adenovirus mediated prostate-specific enzyme pro-drug gene therapy regulated by prostate-specific membrane antigen (PSMA) enhancer/promoter.

Zeng H, Wei Q, Huang R, Chen N, Dong Q, Yang Y, Zhou Q.

J Androl. 2007 Nov-Dec;28(6):827-35. Epub 2007 May 23.

Supplemental Content

Support Center